SMO mutations do not seem to drive multifocal relapse of locally advanced basal cell carcinoma after vismodegib discontinuation.

e21559Background: Vismodegib , a selective Hh pathway inhibitor that targets Smoothened (SMO) is a major therapeutic breakthrough for locally advanced (la) or metastatic BCC. During treatment some ...